Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SI-6603 in Lumbar Disc Herniation
NCT03607838Phase 3Completed
- Sponsor
- Seikagaku Corporation
- Start
- Nov 2018
- Primary completion
- Aug 2022
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of condoliase in lumbar disc herniation (LDH) (2 arms), sponsored by Seikagaku Corporation. Primary endpoint: Change From Baseline in Average Worst Leg Pain Score at 13 weeks. Started Nov 2018; status: completed.
02
Drugs
condoliase
03
Conditions
lumbar disc herniation (LDH)
Beyond the preview
Go deeper on NCT03607838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03607838.